JP2008528467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528467A5 JP2008528467A5 JP2007551742A JP2007551742A JP2008528467A5 JP 2008528467 A5 JP2008528467 A5 JP 2008528467A5 JP 2007551742 A JP2007551742 A JP 2007551742A JP 2007551742 A JP2007551742 A JP 2007551742A JP 2008528467 A5 JP2008528467 A5 JP 2008528467A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- cancer
- compound
- fluorine
- hydrocarbyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- -1 2,6-dichlorophenyl Chemical group 0.000 claims 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 9
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 239000011737 fluorine Substances 0.000 claims 9
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 239000000460 chlorine Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000002837 carbocyclic group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- YPSOVQYHIDHKDO-UHFFFAOYSA-N tert-butyl 4-[[4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl YPSOVQYHIDHKDO-UHFFFAOYSA-N 0.000 claims 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 108091007914 CDKs Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 1
- WIFZVEQCDXYJTR-UHFFFAOYSA-N ethenyl 4-[[4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carbonyl]amino]piperidine-1-carboxylate Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCN(C(=O)OC=C)CC1 WIFZVEQCDXYJTR-UHFFFAOYSA-N 0.000 claims 1
- KSUTVVOXLOPRBX-UHFFFAOYSA-N ethyl 4-[[4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl KSUTVVOXLOPRBX-UHFFFAOYSA-N 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical group COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- KZUNCMJJRARVTM-UHFFFAOYSA-N propan-2-yl 4-[[4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl KZUNCMJJRARVTM-UHFFFAOYSA-N 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64621705P | 2005-01-21 | 2005-01-21 | |
| GB0501480A GB0501480D0 (en) | 2005-01-22 | 2005-01-22 | Pharmaceutical compounds |
| GB0501748A GB0501748D0 (en) | 2005-01-27 | 2005-01-27 | Pharmaceutical compounds |
| US65133905P | 2005-02-09 | 2005-02-09 | |
| PCT/GB2006/000196 WO2006077419A1 (en) | 2005-01-21 | 2006-01-20 | Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528467A JP2008528467A (ja) | 2008-07-31 |
| JP2008528467A5 true JP2008528467A5 (enExample) | 2009-03-19 |
Family
ID=35967182
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551739A Pending JP2008528465A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
| JP2007551742A Pending JP2008528467A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
| JP2007551740A Withdrawn JP2008528466A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋ阻害ピラゾール誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551739A Pending JP2008528465A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551740A Withdrawn JP2008528466A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋ阻害ピラゾール誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080306069A1 (enExample) |
| EP (3) | EP1853600A1 (enExample) |
| JP (3) | JP2008528465A (enExample) |
| KR (3) | KR20070107049A (enExample) |
| AR (3) | AR052559A1 (enExample) |
| AU (3) | AU2006207316A1 (enExample) |
| BR (2) | BRPI0606317A2 (enExample) |
| CA (3) | CA2593656A1 (enExample) |
| IL (3) | IL184502A0 (enExample) |
| MA (3) | MA29253B1 (enExample) |
| MX (3) | MX2007008780A (enExample) |
| NO (3) | NO20073956L (enExample) |
| PE (3) | PE20060876A1 (enExample) |
| TN (3) | TNSN07279A1 (enExample) |
| WO (3) | WO2006077419A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ544756A (en) * | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| TW200533657A (en) | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| WO2006077428A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP2008528469A (ja) * | 2005-01-21 | 2008-07-31 | アステックス・セラピューティクス・リミテッド | ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤 |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
| WO2006077424A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| CN101133088B (zh) * | 2005-03-03 | 2011-04-13 | 三菱丽阳株式会社 | 聚合物粒子、含有它的树脂组合物、成型体 |
| US7897589B2 (en) | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| EP1743890A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
| EP1743892A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| US20090318500A1 (en) * | 2006-05-05 | 2009-12-24 | Astex Therapeutics Limited | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer |
| US20090142337A1 (en) * | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
| EP2046330A2 (en) * | 2006-07-14 | 2009-04-15 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20100004243A1 (en) * | 2006-07-14 | 2010-01-07 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US20090318430A1 (en) * | 2006-07-21 | 2009-12-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| CA2665804A1 (en) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008055966A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| FR2908409B1 (fr) * | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
| FR2913018A1 (fr) * | 2007-02-23 | 2008-08-29 | Sanofi Aventis Sa | Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs |
| EP2267459A1 (en) * | 2009-06-25 | 2010-12-29 | Universite Pierre Et Marie Curie - Paris VI | Method for determining the susceptibility of a cell strain to drugs |
| EP2701510B1 (en) | 2011-04-25 | 2017-02-15 | Usher III Initiative | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| DE102011106990B3 (de) * | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| BRPI1107312B1 (pt) | 2011-11-25 | 2021-09-08 | Universidade Federal De Santa Catarina | Composto de acil-hidrazona |
| US9611249B2 (en) * | 2012-02-12 | 2017-04-04 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| EP2825886A4 (en) * | 2012-03-14 | 2015-11-18 | Stephen Marx | MEDIUM AND METHODS OF DIAGNOSIS AND THERAPY OF ILLNESSES |
| PL2912038T3 (pl) * | 2012-10-25 | 2019-02-28 | Usher Iii Initiative, Inc. | Pirazolopirydazyny oraz sposoby leczenia zwyrodnieniowych chorób siatkówki i utraty słuchu związanych z zespołem ushera |
| US8765762B2 (en) | 2012-10-25 | 2014-07-01 | Usher III, Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
| MX2015007936A (es) | 2012-12-19 | 2016-03-11 | Novartis Ag | Inhibidores de autotaxina. |
| WO2014174846A1 (ja) | 2013-04-25 | 2014-10-30 | 杏林製薬株式会社 | 固形医薬組成物 |
| WO2014179144A1 (en) * | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
| WO2015113927A1 (en) * | 2014-01-29 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| EP2980088A1 (en) | 2014-07-28 | 2016-02-03 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| JP2017528460A (ja) * | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド |
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| KR20230012099A (ko) | 2018-03-27 | 2023-01-25 | 다이킨 고교 가부시키가이샤 | 술팜산리튬의 제조 방법 및 신규 술팜산리튬 |
| PL3764451T3 (pl) | 2018-03-27 | 2023-02-20 | Daikin Industries, Ltd. | Roztwór elektrolitu, urządzenie elektrochemiczne, litowo-jonowa bateria akumulatorowa oraz moduł |
| JP7164821B2 (ja) | 2018-03-27 | 2022-11-02 | ダイキン工業株式会社 | 電解液、電気化学デバイス、リチウムイオン二次電池、モジュール及び化合物 |
| JP7590185B2 (ja) * | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN111848579B (zh) | 2019-04-26 | 2023-11-14 | 君实润佳(上海)医药科技有限公司 | 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药 |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| WO2023072096A1 (zh) * | 2021-10-25 | 2023-05-04 | 优领医药科技(香港)有限公司 | 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用 |
| TW202337434A (zh) * | 2022-02-11 | 2023-10-01 | 美商傳達治療有限公司 | Ｃｄｋ抑制劑及其使用方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282361A (en) * | 1978-03-16 | 1981-08-04 | Massachusetts Institute Of Technology | Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines |
| US5502068A (en) * | 1995-01-31 | 1996-03-26 | Synphar Laboratories, Inc. | Cyclopropylpyrroloindole-oligopeptide anticancer agents |
| US6066738A (en) * | 1996-01-30 | 2000-05-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| EP1264820A4 (en) * | 2000-03-14 | 2004-09-15 | Fujisawa Pharmaceutical Co | amide compounds |
| US6455559B1 (en) * | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| NZ544756A (en) * | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| JP2008528469A (ja) * | 2005-01-21 | 2008-07-31 | アステックス・セラピューティクス・リミテッド | ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤 |
| WO2006077424A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
| WO2006077428A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
-
2006
- 2006-01-19 AR ARP060100204A patent/AR052559A1/es not_active Application Discontinuation
- 2006-01-19 AR ARP060100205A patent/AR052660A1/es not_active Application Discontinuation
- 2006-01-19 AR ARP060100202A patent/AR053662A1/es not_active Application Discontinuation
- 2006-01-20 JP JP2007551739A patent/JP2008528465A/ja active Pending
- 2006-01-20 CA CA002593656A patent/CA2593656A1/en not_active Abandoned
- 2006-01-20 BR BRPI0606317-9A patent/BRPI0606317A2/pt not_active IP Right Cessation
- 2006-01-20 JP JP2007551742A patent/JP2008528467A/ja active Pending
- 2006-01-20 PE PE2006000079A patent/PE20060876A1/es not_active Application Discontinuation
- 2006-01-20 EP EP06700940A patent/EP1853600A1/en not_active Withdrawn
- 2006-01-20 JP JP2007551740A patent/JP2008528466A/ja not_active Withdrawn
- 2006-01-20 MX MX2007008780A patent/MX2007008780A/es not_active Application Discontinuation
- 2006-01-20 CA CA002593465A patent/CA2593465A1/en not_active Abandoned
- 2006-01-20 KR KR1020077018915A patent/KR20070107049A/ko not_active Withdrawn
- 2006-01-20 PE PE2006000081A patent/PE20061198A1/es not_active Application Discontinuation
- 2006-01-20 EP EP06709562A patent/EP1846395A1/en not_active Withdrawn
- 2006-01-20 KR KR1020077018916A patent/KR20070098927A/ko not_active Withdrawn
- 2006-01-20 WO PCT/GB2006/000196 patent/WO2006077419A1/en not_active Ceased
- 2006-01-20 WO PCT/GB2006/000191 patent/WO2006077414A1/en not_active Ceased
- 2006-01-20 AU AU2006207316A patent/AU2006207316A1/en not_active Abandoned
- 2006-01-20 BR BRPI0606107-9A patent/BRPI0606107A2/pt not_active IP Right Cessation
- 2006-01-20 PE PE2006000080A patent/PE20061073A1/es not_active Application Discontinuation
- 2006-01-20 KR KR1020077018917A patent/KR20070098928A/ko not_active Withdrawn
- 2006-01-20 WO PCT/GB2006/000193 patent/WO2006077416A1/en not_active Ceased
- 2006-01-20 EP EP06704677A patent/EP1853584A1/en not_active Withdrawn
- 2006-01-20 AU AU2006207313A patent/AU2006207313A1/en not_active Abandoned
- 2006-01-20 AU AU2006207311A patent/AU2006207311A1/en not_active Abandoned
- 2006-01-20 US US11/814,443 patent/US20080306069A1/en not_active Abandoned
- 2006-01-20 MX MX2007008782A patent/MX2007008782A/es not_active Application Discontinuation
- 2006-01-20 MX MX2007008784A patent/MX2007008784A/es not_active Application Discontinuation
- 2006-01-20 CA CA002593468A patent/CA2593468A1/en not_active Abandoned
- 2006-01-20 US US11/814,446 patent/US20080194562A1/en not_active Abandoned
-
2007
- 2007-07-09 IL IL184502A patent/IL184502A0/en unknown
- 2007-07-09 IL IL184503A patent/IL184503A0/en unknown
- 2007-07-09 IL IL184499A patent/IL184499A0/en unknown
- 2007-07-20 TN TNP2007000279A patent/TNSN07279A1/en unknown
- 2007-07-20 TN TNP2007000281A patent/TNSN07281A1/en unknown
- 2007-07-20 TN TNP2007000278A patent/TNSN07278A1/en unknown
- 2007-07-27 NO NO20073956A patent/NO20073956L/no not_active Application Discontinuation
- 2007-07-27 NO NO20073955A patent/NO20073955L/no not_active Application Discontinuation
- 2007-07-27 NO NO20073960A patent/NO20073960L/no not_active Application Discontinuation
- 2007-08-16 MA MA30143A patent/MA29253B1/fr unknown
- 2007-08-16 MA MA30145A patent/MA29255B1/fr unknown
- 2007-08-16 MA MA30144A patent/MA29254B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528467A5 (enExample) | ||
| JP6013375B2 (ja) | キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体 | |
| KR101964251B1 (ko) | 약학적 화합물 | |
| JP2008528465A5 (enExample) | ||
| JP2009543771A5 (enExample) | ||
| JP2020503299A5 (enExample) | ||
| JP2016513660A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| CA2939164A1 (en) | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | |
| CA2943022C (en) | Benzo[g]pyrido[2,1-b] quinazoline carboxamide compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| WO2017001853A1 (en) | Antiviral compounds | |
| JP2011506402A5 (enExample) | ||
| JP2008505167A5 (enExample) | ||
| CA2771775A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| RU2014153627A (ru) | Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ | |
| JP2017532360A5 (enExample) | ||
| JP6380777B2 (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| JP2011516536A5 (enExample) | ||
| JP2005508953A5 (enExample) | ||
| JP2011513419A5 (enExample) | ||
| JP2022539208A (ja) | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 | |
| JP2009537606A5 (enExample) | ||
| JPWO2021061642A5 (enExample) | ||
| RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
| KR102682516B1 (ko) | 퀴놀린 구조를 갖는 pan-kit 키나제 억제제 및 이의 용도 |